Whitney Tilson is the founder and Managing Partner of Kase Capital Management, which manages three value-oriented hedge funds. Mr. Tilson is also the co-founder of Value Investor Insight, an investment newsletter.
Mr. Tilson has co-authored two books, The Art of Value Investing: How the World's Best Investors Beat the Market (2013) and More Mortgage Meltdown: 6 Ways to Profit in These Bad Times (2009), was one of the authors of Poor Charlie’s Almanack, the definitive book on Berkshire Hathaway Vice Chairman Charlie Munger, and has written for Forbes, the Financial Times, Kiplinger’s, the Motley Fool and TheStreet.com. He was featured in two 60 Minutes segments in December 2008 about the housing crisis (which won an Emmy) and in March 2015 about Lumber Liquidators. He served for two years on the Board of Directors of Cutter & Buck, which designs and markets upscale sportswear, until the company was sold in early 2007.
Mr. Tilson received an MBA with High Distinction from the Harvard Business School, where he was elected a Baker Scholar (top 5% of class), and graduated magna cum laude from Harvard College, with a bachelor’s degree in Government.
Mr. Tilson spent much of his childhood in Tanzania and Nicaragua (his parents are both educators, were among the first couples to meet and marry in the Peace Corps, and have retired in Kenya). Consequently, Mr. Tilson is involved with a number of charities focused on education reform and Africa. For his philanthropic work, he received the 2008 John C. Whitehead Social Enterprise Award from the Harvard Business School Club of Greater New York. He is a member and past Chairman of the Manhattan chapter of the Young Presidents’ Organization. Mr. Tilson lives in Manhattan with his wife and three teenage daughters.
SA PRO author & marketplace contributor. Successful PRO calls include $AKAO (+400% within 6 months) & $MRNS (+450% within 6 months).
I am providing members of my marketplace service, 'Second-Level Investing' with exclusive ideas, analysis and interviews with managers and subject matter experts.
- A former diplomat & entrepreneur. A former Project Manager at UN Principles for Responsible Investment
- An alumni of SciencesPo Paris
- Based in Luxembourg
I am an a biotech/pharma professional who has spent the last 20 years in Healthcare. I am a physician and hold MBA from top five U.S. business school. My experience includes investment banking and strategy consulting for biotech/pharma companies.
I invest with passion and conviction, and I have the strength to stick with an investment until my thesis plays out, hence "Courage & Conviction Investing." My greatest gift is a rare ability to synthesize public information on a stock to formulate conclusions the market hasn't even considered. I share this unique skill with subscribers to my Marketplace service, Market Adventures. High-conviction investing isn't for everyone, but if you're in the market to make serious money and you have an insatiable appetite for risk, and you're willing to wait patiently for potentially big gains, then Market Adventures might be the right fit for you.
“When you are inspired by some great purpose, some extraordinary project, all your thoughts break their bonds: Your mind transcends limitations, your consciousness expands in every direction, and you find yourself in a new, great and wonderful world. Dormant forces, faculties and talents become alive, and you discover yourself to be a greater person by far than you ever dreamed yourself to be.” (Author - Patanjali)
“Tentative efforts lead to tentative outcomes. Therefore, give yourself fully to your endeavors. Decide to construct your character through excellent actions and determine to pay the price of a worthy goal. The trials you encounter will introduce you to your strengths. Remain steadfast...and one day you will build something that endures: something worthy of your potential.” (Author - Epictetus)
"Hope sees the invisible, feels the intangible, and achieves the impossible." (Author - Unknown)
"When I stand before God at the end of my life, I would hope that I would not have a single bit of talent left, and could say, 'I used everything you gave me." (Author - Erma Bombeck)
Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaboration with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI) marketplace research is delivering robust returns since inception. To name a couple winners, Nektar Therapeutics and Spectrum Pharmaceuticals delivered profits of 446% and 196% for our subscribers, respectively. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios. Of note, we’ll increase our price soon (SUBSCRIBE to IBI now to lock in the current price and save money). Click the orange FOLLOW button to receive the FREE real-time alerts on our articles and blogs. To read the FREE once-weekly articles covering promising small-cap bioscience firms, check out www.drtranbiosci.com (and make sure to register for our mailing list). You can read up on Dr. Tran’s background in an in-depth article by following this link. http://www.drtranbiosci.com/p/dr-tran.html "Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
The SA Investor Marketplace is where readers can subscribe to premium research and private communities from top SA authors. Marketplace services cover a wide variety of investment styles, giving readers a chance to invest alongside their favorite authors.
Interested in building a business on Marketplace? Check out this story on authors' success to date, and go here to learn more about writing for SA. Contact us at email@example.com if you'd like to apply to launch a Marketplace service.
Interested in signing up for a Marketplace service? Check out all our authors here. For any questions about SA's Marketplace, contact firstname.lastname@example.org. We'd be happy to hear from you.
This account will be used to highlight these authors and offer insights into investing from the authors to any interested users. Follow this account if you'd like to hear what's going on with the SA Marketplace!
I am an individual investor focused on biotech, technology, and natural resources. I have also recently started covering the marijuana industry.
I often write about undervalued biotech companies with significant potential to disrupt existing markets. I will increasingly cover the market for recreational and medicinal marijuana which is poised to rapidly expand as legalization takes place in Canada and several American states. I am a law student and have spent several years researching the interaction between Indigenous rights and natural resource development in North America, Australia, and New Zealand. Much of my writing on Seeking Alpha focuses on the impact of social, legal, and political factors on the North American resource extraction sector.
Strong Bio is a growth-focused analyst seeking identification of unique investment opportunities in biotechnology that arise as high probability market niche innovation or expansion based on scientific peer-reviewed evidence supportive of novel mechanism(s) of action. By diligently screening investment candidates in multiple biotechnology sectors, initial position recommendations and reinforcing position pricing profiles can be systematically evaluated citing fundamental trends for investors to exploit. If you would like to request that Strong Bio publish an article on a company of interest, please request by private message. Strong Bio reminds the reader that investment in biotechnology can be considered high risk, and diversification of assets is a necessity. Strong Bio is a personal branding of F. Thomas Crump, Ph.D., in an attempt to communicate with a biotechnology stock club that got too large to communicate with by text. Strong Bio mobile app under construction.
I am an investor with a background in biotechnology and genetics. My Ph.D. education and professional experience are focused on genetics, stem cells, CRISPR, next generation sequencing and gene therapy. My investments and investment ideas are focused on long plays on under-appreciated/revolutionary products at the cutting edge of science.
Statbeyond Consulting LLC provides consulting services to analyze/predict drug efficacy for ongoing clinical trials in the biotech space. One of their key strengths is to provide innovative statistical approach to access the success probability of ongoing phase II/III clinical trials by in-depth statistical analysis on publicly available historical data and by extensive simulation on such data based on trial design.
John Balison is a Licensed Professional Engineer, biotech investor and writer. He focuses on late-stage biotech development companies or those in the early phases of commercialization. His secondary focus is on companies involved in the treatment of chronic diseases, primarily end stage renal disease (ESRD), and gastrointestinal disorders.
President of Almington Capital - Merchant Bankers.
Investing in publicly traded securities, private equity, real estate, venture capital.
Taking advantage of deep value opportunities, growth opportunities, and special situations across a range of asset classes and industries.
The Busted IPO Forum founded by Bret Jensen, is a hypothetical $150K portfolio built of stocks that have been public for 18 months to five years that are significantly under their offering price. Many times after the initial analyst hyperbole has died and lockups have expired, these same companies can be had for .30 to .50 cents on the dollar from when the shares went public. As lucrative as this niche has been for Bret's portfolio over the years, a service or newsletter has not existed that covered this segment of the market -- until now! The goal in creating the Busted IPO Forum is to build a portfolio of 15-20 small cap and mid cap busted IPOs which consistently outperform the Russell 2000 over time.
• • •
Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.
• • •
Learn more about Bret Jensen's Marketplace offerings:
The Insiders Forum | The Biotech Forum | Busted IPO Forum
I have been a businessman for over twenty years, a long-term blogger, an investor and a consultant with a focus in the field of biotechnology. My main interest is related to small and medium-sized companies with high growth potential, and a particularly innovative structure.
Slingshot Insights is the first crowdfunded expert network and due diligence community. Members use our suite of tools to cut through the noise and Become the Smart Money. We provide you affordable access to Experts and Management Teams so that you can make informed investment decisions. By grouping investors around project ideas they care about, we pass along significant savings without compromising on quality.
I have 20+ years of experience in biotech investments. I am a chemical engineer and hold a Ph.D. in microbial physiology, but I am not an MD. I have authored or co-authored more than 20 peer reviewed scientific papers.
Private equity, asset management and equity analyst professional with accomplished academic background. Harvard graduate and fellow, INSEAD and London Business School graduate.
Favorite quote: "It is easier to fool people than to convince them that they have been fooled." Mark Twain
Hedge fund manager & Short seller - 10+ years on the buy-side at Multi-Bn Hedge Funds. Now exposing terminal shorts, promotion schemes, and legal frauds.
Tips/ideas on companies misleading investors can be sent to email@example.com. I always welcome collaboration and have respect for your anonymity. There are multiple ways to submit documents anonymously please reach out.
Any proceeds from Seekingalpha.com to Fuzzy Panda will be donated to SIRF Foundation (http://sirf-online.org/donations/) in order to support great investigative reporting.
Seeking Alpha PRO is our premium service for serious investors.
PRO subscribers receive early access to our best long or short ideas - 20-30 articles a week, as selected by our PRO editorial team. They also receive exclusive access to our archive of over 15,000 professional level ideas and research, focused primarily on single equity articles.
We will use this account to publish announcements related to PRO, as well as our PRO Weekly Digest, a new series that will be made available first to PRO subscribers but then to all readers interested in learning about PRO or reading ideas from some of our top authors.
If you're interested in PRO, check out this page for more details. If you'd like to get in touch with our sales team, contact proaccess at seekingalpha.com, and if you'd like to reach our editorial team, write to pro-editors at seekingalpha.com.